Methods for stratification of parkinson's disease patients, systems and uses thereof
AssigneeUniversite Du Luxembourg
InventorsGiuseppe ARENA, Patrick MAY, Rejko KRÜGER, Anne GRÜNEWALD, Zied LANDOULSI
Life of this patent
Estimating the term…
Abstract
The present invention provides for methods for the stratification of Parkinson's disease patients, systems and uses thereof. Provided are methods of diagnosis, uses and methods for screening, compositions and systems.
Claims37
A method for stratifying whether or not a subject may be at a risk of suffering from Parkinson's disease (PD), comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score, wherein a high OXPHOS-mito polygenic risk score is indicative that said subject may be at a risk of developing PD.
A method for stratifying whether or not a subject may be at a risk of suffering from Parkinson's disease (PD), comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score, wherein a low OXPHOS-mito polygenic risk score is indicative that said subject may not be at a risk of developing PD.
A method for stratifying whether or not a subject suffering from Parkinson's disease (PD) may be at a risk of having mitochondrial dysfunction, comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score (PRS), wherein a high OXPHOS-mito PRS is indicative that said subject may be at a risk of developing mitochondrial dysfunction and/or wherein a low OXPHOS-mito PRS is indicative that said subject may not be at a risk of developing mitochondrial dysfunction.
A method for stratifying whether or not a subject may be at risk suffering from Parkinson's disease (PD) with an early age of onset, comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score (PRS), wherein a high OXPHOS-mito PRS is indicative that said subject may be at a risk of developing Parkinson's disease (PD) with an early age of onset and/or wherein a low OXPHOS-mito PRS is indicative that said subject may not be at a risk of developing Parkinson's disease (PD) with an early age of onset.
A compound for use in a method for preventing and/or treating Parkinson's disease in a subject, wherein said subject has a high OXPHOS-mito polygenic risk score.
Use of a cell being characterized by a high OXPHOS-mito polygenic risk score for screening compounds for the prevention or treatment of Parkinson's disease.
A method for screening compounds for the prevention or treatment of Parkinson's disease, comprising bringing a cell being characterized by a high OXPHOS-mito polygenic risk score into contact with said compound and determining whether said compound modulates mitochondrial oxygen consumption of said cell.
A composition comprising a cell being characterized by a high OXPHOS-mito polygenic risk score, optionally further comprising a buffer.
A system comprising a cell being characterized by a high OXPHOS-mito polygenic risk score, optionally further comprising a buffer.
Dependencies are inferred from the claim text.